Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials

BACKGROUND: Funding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study, we review the design assumptions for pivotal ALS clinical trials with time-to-even...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Neurol Neurosurg Psychiatry
Main Authors: van Eijk, Ruben P A, Nikolakopoulos, Stavros, Roes, Kit C B, Middelkoop, Bas M, Ferguson, Toby A, Shaw, Pamela J, Leigh, P Nigel, Al-Chalabi, Ammar, Eijkemans, Marinus J C, van den Berg, Leonard H
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2019
Assuntos:
Neuromuscular
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6902062/
https://ncbi.nlm.nih.gov/pubmed/31292200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2019-320998
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares